Semaglutide denied for failing step therapy by UnitedHealthcare?

BMI >=30, OR BMI >=27 with at least one weight-related comorbidity (T2DM, hypertension, dyslipidemia, CVD, OSA). 6-month documented diet/exercise program. Step therapy: failed/contraindicated phentermine/topiramate or Contrave trial.

Step-therapy: Document contraindications to required agents - phentermine contraindicated in cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, MAOI use within 14 days (FDA prescribing information); phentermine/topiramate contraindicated in pregnancy, glaucoma, hyperthyroidism, MAOI use (FDA prescribing information); naltrexone/bupropion contraindicated in uncontrolled hypertension, seizure disorders, eating disorders, chronic opioid use, abrupt discontinuation of alcohol/benzodiazepines (FDA prescribing information). If prior trial completed: document inadequate response (weight loss <5% after 12 weeks per 2016 AACE/ACE obesity guidelines) or intolerance with specific adverse effects (e.g., tachycardia, insomnia, nausea, headache). Cite semaglutide 2.4mg FDA approval for chronic weight management in adults with obesity or overweight with weight-related comorbidity (June 2021). Reference STEP 1 trial showing semaglutide produced mean 14.9% body weight reduction vs 2.4% with placebo at 68 weeks (NEJM 2021;384:989-1002). Cite AMA recognition of obesity as a disease requiring treatment (2013) and 2016 AACE/ACE obesity algorithm supporting GLP-1 receptor agonists when lifestyle and first-line pharmacotherapy fail or are contraindicated. BMI threshold: Verify FDA indication (BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia). Supervised program: Document prior lifestyle intervention attempts including dietary counseling and increased physical activity per FDA indication requirements. Employer carve-out: Request plan documents confirming exclusion; appeal as medically necessary treatment for chronic disease; consider state parity laws if applicable.

UHC's step-therapy on semaglutide requires documented failure or contraindication of phentermine/topiramate (Qsymia) or naltrexone/bupropion (Contrave) before approval. The denial fires most often when the prescriber's note says "patient tried phentermine" without dose, duration, or outcome — OptumRx's reviewer cannot count an unspecified trial as adequate.

For each prior agent, the appeal needs explicit documentation:

• Drug + brand specifically. UHC accepts phentermine alone with extra documentation, but Qsymia (full-strength 15/92mg) carries more weight in the review. Name the brand explicitly.
• Dose at maximum tolerated. Qsymia 15/92mg, Contrave 32/360mg, phentermine 37.5mg. Document dose escalation up to maximum or the side-effect that prevented escalation.
• Duration ≥3 months at full dose. Shorter trials are rejected unless side-effect-limited with chart-cited reason.
• Outcome at 3 months. Percent weight loss with starting and ending weight. UHC treats <5% weight loss at 3 months as treatment failure justifying step-up to GLP-1.

Cardiovascular contraindications carry significant weight in UHC's review. Phentermine is contraindicated in uncontrolled hypertension, cardiovascular disease history (prior MI, stroke, heart failure), hyperthyroidism, glaucoma, and concurrent MAO-inhibitor use. Contrave is contraindicated in seizure disorder, bulimia, active opioid use, severe hepatic impairment, and uncontrolled hypertension. If any contraindication is on the patient's chart, cite it explicitly with the visit date — UHC accepts contraindication without requiring trial.

A Qsymia-specific contraindication that UHC accepts: kidney stone history (topiramate component), metabolic acidosis history, glaucoma. These are common enough in obesity-associated comorbidity that the contraindication argument often works.

For patients who tried a different GLP-1 (liraglutide/Saxenda, dulaglutide/Trulicity) and discontinued for tolerability, frame this as cross-class step satisfaction rather than within-class. UHC's policy treats failure of any GLP-1 as satisfying the step-therapy requirement for semaglutide.

The federal hook: step-therapy override is required by 29 USC §1185d for ERISA plans when continuation of current therapy is medically appropriate. State step-therapy override laws (Texas Insurance Code §1369.0541, Illinois 215 ILCS 5/356z.21, NY Public Health Law §270-a, California SB-159) apply to fully-insured plans with shorter override timelines than federal ERISA — for fully-insured UHC plans, this can compress review from 30 days to 72 hours.

OptumRx procedural lever: submit the override via the OptumRx Step Therapy Override Request form specifically — generic appeals through UHC medical channels route incorrectly and add 30 days to review.

Closing tactical tip: include the patient's most recent labs (A1c, lipids, BP) showing the trajectory of weight-related comorbidities — UHC's reviewers respond to objective biomarker movement more than to narrative descriptions.